MARCIANO, ROBERTA
 Distribuzione geografica
Continente #
NA - Nord America 344
EU - Europa 251
AS - Asia 108
AF - Africa 18
Totale 721
Nazione #
US - Stati Uniti d'America 339
IT - Italia 152
CN - Cina 45
SG - Singapore 45
NL - Olanda 36
CI - Costa d'Avorio 18
IE - Irlanda 18
SE - Svezia 11
FI - Finlandia 10
FR - Francia 10
DE - Germania 8
IN - India 7
CA - Canada 5
JO - Giordania 4
BE - Belgio 3
GB - Regno Unito 2
IR - Iran 2
PK - Pakistan 2
ES - Italia 1
IL - Israele 1
MM - Myanmar 1
UZ - Uzbekistan 1
Totale 721
Città #
Chandler 75
Amsterdam 36
Singapore 35
Naples 34
Napoli 33
Ashburn 29
Beijing 15
Millbury 15
Santa Clara 14
Princeton 12
Nanchang 8
Boston 6
Des Moines 6
Hicksville 6
Munich 6
Nanjing 6
San Mateo 6
Caserta 5
Ottawa 5
Pune 5
Amman 4
Fucecchio 4
Lawrence 4
Seattle 4
Washington 4
Boardman 3
Casagiove 3
Falls Church 3
Formia 3
Hebei 3
Rome 3
Turin 3
Afragola 2
Ardabil 2
Edegem 2
Prato 2
Redwood City 2
San Giorgio a Cremano 2
Shenyang 2
Yellow Springs 2
Augusta 1
Baiano 1
Bangalore 1
Casoria 1
Changchun 1
Changsha 1
Changzhou 1
Falkenstein 1
Helsinki 1
Islamabad 1
Jacksonville 1
Jiaxing 1
Kronberg 1
La Louvière 1
Leawood 1
Marigliano 1
Milan 1
Montalbano Jonico 1
Montesilvano Marina 1
Mountain View 1
Nay Pyi Taw 1
Palermo 1
Paris 1
Paterno 1
Pizzo 1
Pomigliano d'Arco 1
Pozzuoli 1
Prineville 1
Rawalpindi 1
Redmond 1
San Giorgio A Cremano 1
San Jose 1
San Mango Piemonte 1
Sarno 1
Sesto Fiorentino 1
Shanghai 1
Tashkent 1
Tel Aviv 1
Wilmington 1
Totale 453
Nome #
Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors 92
Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status 53
Addition of erlotinib to fluoropyrimidine-oxaliplatin-basedchemotherapy with or without bevacizumab: Two sequential phase I trials 52
From biology to therapy: Improvements of therapeutic options in Lung cancer 48
Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis. 47
Mechanisms of resistance to mTOR inhibitors 46
FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules 44
Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review. 43
Use of folfirinox or nab-paclitaxel plus gemcitabine for the treatment of locally advanced pancreatic adenocarcinoma: A single institution observational study 43
Everolimus induces Met inactivation by disrupting the FKBP12/Met complex 42
Role of sphingosine kinase 1 (SphK1) on cetuximab resistance in colorectal cancer models 40
Phase I-II study of xelox and bevacizumab plus erlotinib in sequential combination (XELOX-TARAV) in first line colorectal cancer: run in part 39
High-rsolution melting analysis (HRMA) for KRAS mutatiinal study in patients with metastatic colorectal cancer (mCRC pts) 35
Delayed response to maintenance therapy after first-line chemotherapy in metastatic intrahepatic cholangiocarcinoma: A case report 32
Correlation between bevacizumab-related hypertension and response in mCRC patients 30
KRAS mutation detection by high resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer 26
FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study 25
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trial 21
Totale 758
Categoria #
all - tutte 3.486
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.486


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202041 0 0 0 0 8 7 0 1 1 5 16 3
2020/202153 2 0 4 0 6 6 1 5 12 3 13 1
2021/2022126 1 0 4 10 0 4 2 4 20 10 36 35
2022/2023204 22 12 6 7 26 28 3 23 23 38 11 5
2023/2024141 4 18 23 13 6 24 1 23 0 0 19 10
2024/202579 21 19 6 11 22 0 0 0 0 0 0 0
Totale 758